Clinical Trial Update: Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants [Phase 2]

View source ↗

Summary

Phase 2 trial update on the recombinant human papillomavirus nonavalent vaccine for preventing HPV infection in younger healthy participants; results have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Cervical Cancer
• Human Papillomavirus Infection
• Oropharyngeal Cancer
• Penile Cancer
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Human Papillomavirus-Related Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-04-05